RGNX
REGENXBIO Inc.
NASDAQ · USHealthcareBiotechnology
$10.32+4.35%
Price as of Jul 20, 2026
RGNX financials
REGENXBIO Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M |
| Cost of revenue | $20.3M | $33.6M | $37.2M | $54.5M |
| Gross profit | $150.1M | $49.8M | $53.0M | $58.2M |
| Operating expenses | $311.3M | $283.1M | $321.2M | $321.1M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M |
| EBITDA | -$133.3M | -$198.2M | -$239.5M | -$244.2M |
| Basic EPS | $-3.76 | $-4.59 | $-6.02 | $-6.50 |
| Diluted EPS | $-3.76 | $-4.59 | $-6.02 | $-6.50 |
| Balance sheet | ||||
| Cash & equivalents | $34.5M | $57.5M | $34.5M | $97.0M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M |
| Stockholders’ equity | $102.7M | $259.7M | $311.7M | $516.2M |
| Total debt | $260.5M | $82.0M | $89.3M | $94.8M |
| Net debt | $226.1M | $24.5M | $54.8M | -$2.2M |
| Cash flow | ||||
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M |
| Capital expenditure | -$2.4M | -$2.4M | -$10.0M | -$30.7M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $1.2M | $0.00 | $0.00 |